Publications of Faculty of Medicine:Pharmacology and Safety ofTetradecylthioacetic Acid (TTA): Phase-1 Study: Abstract

Pharmacology and Safety ofTetradecylthioacetic Acid (TTA): Phase-1 Study
Full paper Not Available

This study describes the clinical, hematological, and biochemical safety of tetradecylthioacetic acid (TTA). A total of 18 healthy volunteers were included Subjects were randomly assigned into 3 groups according to the daily given dose of TTA: group 1 (200 tog), group 2 (600 mg), and group 3 (1000 mg). TTA was given as a single oral dose for 7 consecutive days. Safety was evaluated by following the adverse events, vital signs, and hematological and biochemical parameters in blood and urine samples. Efficacy was estimated through its effects on plasma lipids profile. Few adverse events of mild severity were reported No clinically significant changes were observed in the hematological or clinical chemical parameters in blood/urine. TTA did not induce significant changes in the blood lipids or free fatty acids, but it did result in an increase m plasma concentration of A9 desaturated TTA (TTA: ln-8). Serum concentration pattern ofTTA at day 1 showed a 1.5-hour lag time followed by a rapid absorption and a slower elimination phase. The median peak values were 2.9 mg^L (range, 1.1 to 5.4 mg/L), 11.5 mg/L (range, 4 to 35 mg/L), and 11 mg/L (range, 5 to 25 mg/L), in groups 1, 2, and 3, respectively (P= 0.006). The time to peak levels were 3.5 horns (range, 2.5 to 6.5 hours), 2.5 hours (range, 2.5 to 4.5 hours), and 4.5 hours (range, 2.5 to 12 hours), respectively (P= 0.2). TTA is safe and well tolerated